A Clinical Phase 1 Study Investigating ACI-3024 for the Treatment of Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2019
Price : $35 *
At a glance
- Drugs ACI 3024 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- 20 Sep 2019 According to an AC Immune media release, company will receive the first milestone payment of CHF30 million from Eli Lilly and Company on or before October 7, 2019 follows initiation of this study.
- 17 Jul 2019 According to an AC Immune media release, the first patient has been dosed for this study.
- 17 Jul 2019 Status changed from planning to recruiting, according to an AC Immune media release.